SIRT treatment enhances the survival in colorectal cancer patients with isolated liver metastases: P114


    loading  Checking for direct PDF access through Ovid

Abstract

Aim:To evaluate the effects of intra-arterial radionuclide treatment (SIRT) in patients with metastatic colorectal cancer pts.Method:Totally 16 colorectal cancer pts, median age 61.5, with unresectable and chemoresistant metastases were qualified to SIRT treatment between May 2008 to June 2009. All cases were evaluated for liver functions and the ones with transaminases more than five times of normal and total bilirubin above 2 mg/dl were excluded. All cases scanned by 18F-FDG PET/CT initially for staging and 4-6 weeks after treatment for follow up. All cases were also evaluated angiographically for the rate of shunt to lungs (MAA note to Ed Im not sure what this test is and it is not defined test < 10%).Results:18F-FDG PET/CT scans showed metastatic disease isolated to liver in eight cases and disease was beyond the liver (lungs, bone, adrenal) in the other eight. No serious side effects were detected. The average follow up period was 14.6 months. All patients with isolated liver metastases were alive in May 2010 and all with extra-hepatic disease had died. Survival curves have been analyzed by Kaplan-Meier method.Conclusion:SIRT treatment significantly increases the survival of patients with isolated liver metastatic colorectal cancer, but its effect with further tumour dissemination is questionable.

    loading  Loading Related Articles